CHARACTERISTICS OF EUGENOL PRODUCTS AND IN VITRO RELEASE IN GEL BASE WITH HYDROXYPROPYL METHYLCELLULOSE (HPMC) VARIANT AS GELLING AGENT

Objective: This research was conducted to examine the characteristics of the eugenol gel preparation in the Hydroxypropyl Methylcellulose (HPMC) gel base and to determine the profile of the release of eugenol from the HPMC gel base. Methods: Eugenol was made into gel preparations using HPMC base with concentrations of 3%, 5% and 7%. The evaluation included the tests of product characteristic and eugenol release. The product characteristic test included organoleptic examination (texture, color, and odor) and tests of spreadability, adhesion, and pH. The release test was carried out using cell diffusion and cellophane membranes. Results: All formulas met the pH requirements of topical products that were safe to use. The spreadability test is between 2.97-6.27 cm, adhesion test of products>4 s. The percentage of determination of eugenol content in the gel formula (F1 105.81%), (F2 93.28%) and (F3 98.87%). The cumulative amount of eugenol was F1 (2.563 mg/cm2), F2 (2.224 mg/cm2), and F3 (1.895 mg/cm2). Conclusion: The variation of HPMC as a gel base has effects on the adhesion, spreadability, and the eugenol gel release profile, where the greater the HPMC concentration, the smaller the spreadability, the greater the adhesion, and the lower the eugenol release profile. Based on the data obtained, the Formula 1 had a better release rate.

Download Full-text

ISE-potentiometric sensor for the determination of zolmitriptan: applications in plasma, pharmaceutical formulation and in vitro release profile

New Journal of Chemistry ◽

10.1039/c8nj03203c ◽

2018 ◽

Vol 42 (18) ◽

pp. 15263-15269 ◽

Cited By ~ 2

Author(s):

Ahmed S. Saad ◽

Mohamed R. El-Ghobashy ◽

Nada S. Ayish ◽

Badr A. El-Zeany

Keyword(s):

Receptor Agonist ◽

Serotonin Receptor ◽

In Vitro Release ◽

Release Profile ◽

Potentiometric Sensor ◽

Potentiometric Determination ◽

Acute Migraine ◽

Vitro Release

Six different sensors were fabricated and compared for the potentiometric determination of a widely used serotonin receptor agonist zolmitriptan (ZT), which is mainly used for the treatment of acute migraine attacks.

Download Full-text

DEVELOPMENT OF FLOATING GASTRORETENTIVE DRUG DELIVERY SYSTEM BASED ON A NOVEL EXCIPIENT FOR METFORMIN HYDROCHLORIDE USING MIXTURE DESIGN

International Journal of Pharmacy and Pharmaceutical Sciences ◽

10.22159/ijpps.2020v12i10.38678 ◽

2020 ◽

pp. 62-71

Author(s):

R. PAWAR ◽

S. JAGDALE ◽

D. RANDIVE

Keyword(s):

Drug Release ◽

Release Kinetics ◽

Hydroxypropyl Methylcellulose ◽

In Vitro Release ◽

Mixture Design ◽

Release Profile ◽

Metformin Hydrochloride ◽

Matrix Tablet ◽

Vitro Release

Objective: The present study aimed to develop a new SR metformin hydrochloride (MH) gastroretentive formulation with novel excipient (NE), which has better floatation and can be prepared with more simple pharmaceutical techniques for the treatment of diabetes Mellitus. Methods: A gastro-retentive floating matrix tablet (GFT) formulation of MH was prepared using various concentrations of PEO (Polyox WSR-303) and hydroxypropyl methylcellulose K100M (HPMC K100 M) and Floating agent (novel excipient) to achieve desirable TFT, FLT and drug release. The wet granulation method was selected using isopropyl alcohol as a binder for the preparation of tablets. D-optimal non-simplex mixture design was used for the selection of suitable polymer concentrations and floating agents. Release kinetics was used to determine the mechanism of drug release. Results: It was observed that GFT with optimum quantities of PEO, HPMC K100M, and the floating agent showed 100 % of drug release in 24h with FT up to 24h and minimum FLT of less than 2 min. Formulation with an in vitro release profile slower to the marketed sample was prepared. Conclusion: A sustained-release (GFT) of MH tablets using PEO-, HPMC K100M, and an effervescent system was successfully prepared. AGFT formulation with an in vitro release profile slower to the marketed sample that releases MH for 24h may suitable for once-daily dosing can be prepared.

Download Full-text

OPHTHALMIC IN-SITU SUSTAINED GEL OF CIPROFLOXACIN, PREPARATION AND EVALUATION STUDY

International Journal of Applied Pharmaceutics ◽

10.22159/ijap.2018v10i4.26885 ◽

2018 ◽

Vol 10 (4) ◽

pp. 153 ◽

Cited By ~ 1

Author(s):

Fadia Yassir Al-bazzaz ◽

Myasar Al-kotaji

Keyword(s):

Hydroxypropyl Methylcellulose ◽

In Vitro Release ◽

Poloxamer 407 ◽

Gelling Agent ◽

In Situ Gel ◽

Viscosity Modifier ◽

Vitro Release

Objective: This work aims to formulate and evaluate an ophthalmic in-situ gel of ciprofloxacin hydrochloride (HCl) using poloxamer 407 (P407) as a gelling agent and hydroxypropyl methylcellulose (HPMC) as a viscosity modifier. The objective of this work was to prolong the contact time as the in-situ gel will be converted into a gel upon contact with the cul-de-sac. Methods: Ciprofloxacin HCl ophthalmic in-situ gel was prepared by utilizing (P407) as a temperature-dependent polymer while hydroxypropyl methylcellulose was used as a viscosity modifier. The system was evaluated for physical appearance, pH, drug content, sterility, irritancy and stability. In addition, gelation temperature and a viscosity at different shear rates and different temperatures were studied. The compatibility of the polymer with ciprofloxacin was studied by using fourier transform infrared spectroscopy (FTIR). The in vitro release of the drug was also evaluated and supported by a preliminary in vivo test.Results: The results showed that the prepared formulas were clear, with acceptable pH and the drug contents were within the acceptable limits. FTIR results detected no incompatibility between poloxamer 407 and ciprofloxacin HCl. Notably, the viscosity of the system showed a pseudoplastic behaviour where a reduction in viscosity upon increasing the shear rate was observed. The in vitro release study confirmed the prolongation of the release of the optimized formula (F6) up to 8 h. Upon application of F6 into eyes of rabbits there was no irritancy. In addition, in vivo elimination study showed a prolonged contact for the in-situ gel in comparison with the rapid clearance of eye drop. Stability study indicated the stability of the optimized formula (F6). Conclusion: The prepared optimized formula (F6) represents a successful, safe, stable and prolonged release in-situ gel formula of ciprofloxacin.

Download Full-text

Determination of In Vitro Release Profile of PB-1203 (A Drug Candidate that Undergoes Hydrolysis in the Dissolution Medium) in Tablet Formulation by UV-Vis Spectrophotometry

10.26226/morressier.57d6b2bcd462b8028d88e5a6 ◽

2016 ◽

Author(s):

Wei Pan

Keyword(s):

In Vitro Release ◽

Release Profile ◽

Tablet Formulation ◽

Drug Candidate ◽

Dissolution Medium ◽

Vitro Release

Download Full-text

A Study of the in Vitro Release Profile of a New Prostaglandin E2Delivery System for Local Administration in Obstetrics

Acta Obstetricia Et Gynecologica Scandinavica ◽

10.3109/00016348309155199 ◽

1983 ◽

Vol 62 (s113) ◽

pp. 59-61 ◽

Cited By ~ 1

Author(s):

A. S. Harris ◽

P. Stenberg ◽

U. Ulmsten

Keyword(s):

In Vitro Release ◽

Release Profile ◽

Local Administration ◽

Vitro Release

Download Full-text

Development and In Vitro Characterization of Paclitaxel Loaded Solid Lipid Nanoparticles

Current Nanomedicine ◽

10.2174/2405461503666180518093824 ◽

2019 ◽

Vol 9 (1) ◽

pp. 76-85 ◽

Cited By ~ 1

Author(s):

R. Nithya ◽

K. Siram ◽

R. Hariprasad ◽

H. Rahman

Keyword(s):

Zeta Potential ◽

Solid Lipid Nanoparticles ◽

In Vitro Release ◽

Lipid Nanoparticles ◽

Release Profile ◽

Mcf7 Cells ◽

Solid Lipid ◽

Cancerous Cells ◽

Vitro Release

Background: Paclitaxel (PTX) is a potent anticancer drug which is highly effective against several cancers. Solid lipid nanoparticles (SLNs) loaded with anticancer drugs can enhance its toxicity against tumor cells at low concentrations. Objective: To develop and characterize SLNs of PTX (PSLN) to enhance its toxicity against cancerous cells. Method: The solubility of PTX was screened in various lipids. Solid lipid nanoparticles of PTX (PSLN) were developed by hot homogenization method using Cutina HR and Gelucire 44/14 as lipid carriers and Solutol HS 15 as a surfactant. PSLNs were characterized for size, morphology, zeta potential, entrapment efficiency, physical state of the drug and in vitro release profile in 7.4 pH phosphate buffer saline (PBS). The ability of PTX to enhance toxicity towards cancerous cells was tested by performing cytoxicity assay in MCF7 cell line. Results: Solubility studies of PTX in lipids indicated better solubility when Cutina HR and Gelucire 44/14 were used. PSLNs were found to possess a neutral zeta potential with a size range of 155.4 ± 10.7 nm to 641.9 ± 4.2 nm. In vitro release studies showed a sustained release profile for PSLN over a period of 48 hours. SLNs loaded with PTX were found to be more toxic in killing MCF7 cells at a lower concentration than the free PTX.

Download Full-text

LINAGLIPTIN AND GLICLAZIDE DI-LOADED EXTENDED-RELEASE NANOPARTICLES: FORMULATION AND EVALUATION

Wiadomości Lekarskie ◽

10.36740/wlek202109212 ◽

2021 ◽

Vol 74 (9) ◽

pp. 2315-2322

Author(s):

Firas Aziz Rahi ◽

Muath Sheet Mohammed Ameen ◽

Mohammed Shamil Fayyadh

Keyword(s):

Particle Size ◽

Xanthan Gum ◽

Extended Release ◽

Hydroxypropyl Methylcellulose ◽

In Vitro Release ◽

Entrapment Efficiency ◽

Hplc Method ◽

Electronic Microscopy ◽

Vitro Release

The aim: This work aimed to formulate gliclazide and linagliptin extended-release nanoparticles. Materials and methods: A HPLC method was developed and validated to determine gliclazide and linagliptin at the same time without interference. The nanoparticles were prepared by emulsion solvent evaporation using two polymers, namely hydroxypropyl methylcellulose (HPMC) 4000 cps and xanthan gum. Results: Nanoparticles prepared were characterized for drug contents, production yield and entrapment efficiency, zeta potential, particle size, morphology by transmission electronic microscopy (TEM) and in-vitro release rate. The formulae GLH1, GLX1 and GHX1 showed release of linagliptin more than 75% after 8 hrs. While the only formula among the three (GHX1) showed release of gliclazide more than 80% after 8 h. So, the formula GHX1 showed acceptable release of more than 80% of both gliclazide and linagliptin after 8 h. Conclusions: The formula GHX1 which containing (0.5:1 xanthan gum: drugs) was the best nanoparticles formula which released more than 80% of both drugs after 8 h and could achieve good extended release over 24 h.

Download Full-text